ReviewCancer metastasis reviews2010
Why not treat human cancer with interleukin-1 blockade?
Review in Cancer metastasis reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 277 citations in OpenAlex.
- Effect of Vitamin D3 Supplementation in Combination with Weight Loss on Inflammatory Biomarkers in Postmenopausal Women: A Randomized Controlled Trial.Cancer prevention research (Philadelphia, Pa.) · 2015Trial
- Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study.BioMed research international · 2015Trial
- Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.British journal of cancer · 2013Trial
- IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy.NPJ precision oncology · 2026Article
- Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLC.Cancers · 2025Article
- The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications.Molecular cancer · 2025Review
- Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.Frontiers in pharmacology · 2025Article
- Association of Inflammation and Immune Cell Infiltration with Estrogen Receptor Alpha in an Estrogen and Ionizing Radiation-Induced Breast Cancer Model.International journal of molecular sciences · 2024Article
- Causal association of circulating cytokines with the risk of lung cancer: a Mendelian randomization study.Frontiers in oncology · 2024Article
- ASPORIN: A root of the matter in tumors and their host environment.Biochimica et biophysica acta. Reviews on cancer · 2024Review
- NLRP3 and cancer: Pathogenesis and therapeutic opportunities.Pharmacology & therapeutics · 2023Review
- Article
- Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential.Frontiers in genetics · 2023Review
- NLRP3 inflammasome-induced pyroptosis in digestive system tumors.Frontiers in immunology · 2023Review
- Development and validation of a pyroptosis-related genes signature for risk stratification in gliomas.Frontiers in genetics · 2023Article
- Does IFITM3 link inflammation to tumorigenesis?BMB reports · 2022Review
- NLRP1 in Cutaneous SCCs: An Example of the Complex Roles of Inflammasomes in Cancer Development.International journal of molecular sciences · 2022Review
- Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System.Cancers · 2022Review
- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.Nature reviews. Immunology · 2022Review
- The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype.Frontiers in oncology · 2022Review
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
The clinical successes of targeting angiogenesis provide a basis for trials of interleukin-1 (IL-1) blockade and particularly anti-IL-1beta as an add-on therapy in human metastatic disease. In animal studies for over 20 years, IL-1 has been demonstrated to increase adherence of tumor cells to the endothelium in vitro, and administration of IL-1 to mice increases the number of metastatic colonies and tumor growth. Importantly, reducing endogenous IL-1 activity, particularly IL-1beta, with the naturally occurring IL-1 receptor antagonist (IL-1Ra) reduces both metastasis as well as tumor burden. Inhibition of IL-1 activity prevents in vivo blood vessel formation induced by products released from hypoxic macrophages or vascular endothelial cell growth factor itself. Mice deficient in IL-1beta do not form blood vessels in matrigels embedded with vascular endothelial cell growth factor or containing products of macrophages. Recombinant IL-1Ra (anakinra) has been administered to over 1,000 patients with septic shock resulting in a consistent reduction in all-cause 28-day mortality. Approved for treatment of rheumatoid arthritis, anakinra has a remarkable safety record. Anakinra resulted in decreased blood vessels in the pannus of affected joints in patients with rheumatoid arthritis. Neutralizing monoclonal antibodies to IL-1beta and a soluble receptor to IL-1 are approved for treating chronic inflammatory diseases. Given the availability of three therapeutic agents for limiting IL-1 activity, the safety of blocking IL-1, and the clear benefit of blocking IL-1 activity in animal models of metastasis and angiogenesis, clinical trials of IL-1 blockade should be initiated, particularly as an add-on therapy of patients receiving antiangiogenesis-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.